Evidence map›Paper›PMID 37938431›Full record

Observational studyJournal of cancer survivorship : research and practice2025

Trends in physical functioning in acute lymphoblastic leukemia and non-Hodgkin lymphoma survivors across three decades.

Carmen L Wilson, Kari L Bjornard, Robyn E Partin, Nina S Kadan-Lottick, Paul C Nathan, Kevin C Oeffinger, Robert J Hayashi, Geehong Hyun, Gregory T Armstrong, Wendy M Leisenring and 6 more

Registry-linked trialAbstract readObservational Study
In one paragraph

Observational study in Journal of cancer survivorship : research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01120353 (Childhood Cancer Survivor Study), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01120353 recruitingnot on this map

Childhood Cancer Survivor Study

TypeobservationalSponsorSt. Jude Children's Research HospitalRan1995 to 2026Enrolled50,000ConditionsCancer
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

Carmen L WilsonDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA. carmen.wilson@stjude.org.
Kari L BjornardDepartment of Hematology/Oncology, Riley Children's Hospital, Indianopolis, IN, USA.
Robyn E PartinDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.
Nina S Kadan-LottickCancer Prevention and Control Program, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
Paul C NathanDivision of Hematology/Oncology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Kevin C OeffingerDepartment of Medicine, Duke University, Durham, NC, USA.
Robert J HayashiDepartment of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.
Geehong HyunDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.
Gregory T ArmstrongDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.
Wendy M LeisenringCancer Prevention and Clinical Statistics Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Rebecca M HowellRadiation Physics Department, The University of Texas at MD Anderson Cancer Center, Houston, TX, USA.
Yutaka YasuiDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.
Stephanie B DixonDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.
Matthew J EhrhardtDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.
Leslie L RobisonDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.
Kirsten K NessDepartment of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA.
St. Jude Children's Research Hospital · USDuke University · USFred Hutch Cancer Center · USGeorgetown University Medical Center · USHospital for Sick Children · CARiley Hospital for Children · USThe University of Texas MD Anderson Cancer Center · USWashington University in St. Louis · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
Mach-LETSGO: Machine-LEarning of Treatment, Survey, and Genetics towards Obtaining Correct Classification of Chronic Conditions in Adult Survivors in the Childhood Cancer Survivor Study - CCSS SupplU24CA055727 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Gregory Armstrong · 1999 to 2026
$96.7M
CHILDHOOD CANCER SURVIVOR STUDYU01CA055727 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI ROBISON, LESLIE L · 1993 to 1999
–
NCI NIH HHS P30 CA021765NCI NIH HHS P30CA21765NCI NIH HHS U01CA055727NCI NIH HHS U24 CA055727
6 · The paper itself

Abstract

purposeThe impact of changes in therapy for childhood acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) on the prevalence of physical performance limitations and participation restrictions among survivors is unknown. We aimed to describe the prevalence of reduced function among ALL and NHL survivors by treatment era.

methodsParticipants included survivors of childhood ALL and NHL, and a cohort of their siblings, participating in the Childhood Cancer Survivor Study (CCSS). Physical function was measured using questionnaire. The prevalence of reduced function was compared to siblings using generalized estimating equations, overall and stratified by treatment decade. Associations between organ system-specific chronic conditions (CTCAE v4.03) and function were also evaluated.

resultsAmong 6511 survivors (mean age 25.9 years (standard deviation 6.5)) and 4127 siblings, risk of performance limitations (15.2% vs. 12.5%, prevalence ratio [PR] = 1.5, 95%CI = 1.3-1.6), restrictions in personal care (2.0% vs. 0.6%, PR = 3.1, 95% CI = 2.0-4.8), routine activities (5.5% vs. 1.6%, PR = 3.6, 95% CI = 2.7-4.8), and work/school attendance (8.8% vs. 2.1%, PR = 4.5, 95% CI = 3.6-5.7) was increased in survivors vs. siblings. The prevalence of survivors reporting reduced function did not decrease between the 1970s and 1990s. The presence of neurological and cardiovascular conditions was associated with reduced function regardless of treatment decade.

conclusionsDespite changes in therapy, the prevalence of poor physical function remained constant between the 1970s and 1990s. The CCSS clinical trial registration number is NCT01120353 (registered May 6, 2010). IMPLICATIONS FOR CANCER SURVIVORS: Our findings support screening for reduced physical function so that early interventions to improve physical performance and mitigate chronic disease can be initiated.

Indexed as

Cancer SurvivorsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultChildFemaleHumansMaleQuality of LifeYoung AdultChildhood cancerDisabilityParticipation restrictionsPerformance limitationsSurvivor

Identifiers

PMID37938431
PMCPMC11076414
OpenAlexW4388499289

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.